AphaMol developed a new machine learning algorithm
AlphaMol has successfully predicted drug molecule kinetic property through machine learning. It has been published recently as a cover story in the ACS J. Chem. Theory Comput.
Read moreWe are the Intelligent Molecule Creators. We aim at discovering and developing new drug molecules to treat major human disorders and diseases including those against infections, cancers, Alzheimer's disease, diabetes, aging and others. We primarily focus on G protein-coupled receptors (GPCRs) related signalling pathway.
AlphaMol accelerates GPCR drug discovery in an ultimately efficient way
The position for senior medicinal chemist requests a M.S. (10-15 years) or PhD (8-10 years) in medicinal chemistry, with extensive drug discovery experience in industry. The successful... Reed More
Ph.D. or MS after 5 years of graduation in pharmacology, Immunology, Cell Biology, Molecular Biology or related field with 5+ years or M.S. with 10+ years of relevant experience... Reed More
AlphaMol has successfully predicted drug molecule kinetic property through machine learning. It has been published recently as a cover story in the ACS J. Chem. Theory Comput.
Read moreThe latest work of AlphaMol, which is entitled "Computational drug development for membrane protein targets", has been published in Nature Biotechnology
Read moreThe 8th GPCR iHuman Forum was held at the ShanghaiTech University Conference Center from October 18th to 20th, 2023. The cofounder of AlphaMol, Dr. Shuguang Yuan, was invited to this event to give a presentation.
Read moreRecently, AlphaMol received milestone payments from both Shanghai Pharma and Salubris Pharma for the co-developing orphan GPCR drug discovery pipeline.
Read moreThe paper enttiled "Advancing Drug Discovery via Artificial Intelligence" by the team member of AlphaMol has been in the list of Highly Cited Article (HCA). The total citation of this work is over 310 times by April 2023.
Read moreBy resolving the 3D structure of this important target Panx2 coupled with computational simulations, the molecular mechanisms were illuminated which could guide Panx2-based drug discovery for brain cancer.
Read moreThe cofounders of AlphaMol Dr. Horst Vogel and Dr. Shuguang Yuan are among World’s Top 2% Scientists in the 2022 list.
Read moreAlphaMol presented in the international GPCR conference
Read moreAlphaMol Science has obtained the top outstanding award from NVIDIA Inception contest program.
Read more
© 2023 All rights are reserved by AlphaMol Science Ltd